Deferoxamine mesylate; 138-14-7; Desferrioxamine B mesylate; Desferal; Deferoxamine mesilate; Desferrioxamine mesylate; Deferoxamine B mesylate; Deferoxamine (mesylate); Deferoxamine methanesulfonate; Desferal mesylate; UNII-V9TKO7EO6K; Desferioxamine mesylate; V9TKO7EO6K; DESFERRIOXAMINE MESILATE; MLS000028713; Desferrioxamine B mesylate;DFOM; MFCD00058605; 138-14-7 (MESYLATE); NCGC00017021-01; CAS-138-14-7; Desferal (TN); Deferoxamine-D8 mesylate; Deferoxamine mesylate salt; DSSTox_CID_17649; DSSTox_RID_79351; DSSTox_GSID_37649; N-[5-[[4-[5-[acetyl(hydroxy)amino]pentylamino]-4-oxobutanoyl]-hydroxyamino]pentyl]-N'-(5-aminopentyl)-N'-hydroxybutanediamide;methanesulfonic acid; Desferal methanesulfonate; DFX mesylate; CHEBI:31460; N4-[5-[[4-[[5-(acetylhydroxyamino)pentyl]amino]-1,4-dioxobutyl]hydroxyamino]pentyl]-N1-(5-aminopentyl)-N1-hydroxy-butanediamide, monomethanesulfonate; NSC644468; SR-01000695424; SMR000058548; EINECS 205-314-3; Ba 33122; 138D147; Desferrioxamine mesylate salt; CCRIS 8311; Deferoxamine methanesulfonate salt; C26H52N6O11S; Deferoxamine mesylate [USAN:USP]; Prestwick_988; Deforoxamine B mesylate; CHEMBL1234; Deferoxamine mesylate, 95%; Deferoxamine mesylate (USP); N-(5-(3-((5-Aminopentyl)hydroxycarbamoyl)propionamido)pentyl)-3-((5-(N-hydroxyacetamido)pentyl)carbamoyl)propionohydroxamic acid monomethanesulfonate (salt); SCHEMBL119982; SPECTRUM1500224; Deferoxamine mesilate (JP17); DTXSID6037649; HMS500E04; HMS1570A12; HMS1920C16; HMS2091K08; HMS2097A12; HMS2234H23; HMS3714A12; Pharmakon1600-01500224; BCP31290; EX-A4085; HY-B0988; Tox21_110741; CCG-39770; NSC756718; s5742; AKOS026750165; Tox21_110741_1; CS-4479; NSC-644468; NSC-756718; NCGC00017021-02; NCGC00017021-03; NCGC00094640-01; NCGC00094640-02; NCGC00178802-06; Butanediamide, N'-(5-((4-((5-(acetylhydroxyamino)pentyl)amino)-1,4-dioxobutyl)hydroxyamino)pentyl)-N-(5-aminopentyl)-N-hydroxy-, monomethanesulfonate; Deferoxamine Mesylate - CAS 138-14-7; Propionohydroxamic acid, N-(5-(3-((5-aminopentyl)hydroxycarbamoyl)propionamido)pentyl)-3-((5-(N-hydroxyacetamido)pentyl)carbamoyl)-, monomethanesulfonate (salt); AB0035971; DB-042415; FT-0603121; Y0490; D01186; A807339; SR-01000695424-2; SR-01000695424-3; SR-01000695424-4; Deferoxamine mesylate salt, powder, >=92.5% (TLC); Q27114315; Desferrioxamine B mesylate; DFOM;Desferrioxamine mesylate; Deferoxamine mesylate salt, European Pharmacopoeia (EP) Reference Standard; Deferoxamine mesylate, United States Pharmacopeia (USP) Reference Standard; Deferoxamine for system suitability, European Pharmacopoeia (EP) Reference Standard; N'-(5-azanylpentyl)-N-[5-[[4-[5-[ethanoyl(oxidanyl)amino]pentylamino]-4-oxidanylidene-butanoyl]-oxidanyl-amino]pentyl]-N'-oxidanyl-butanediamide; methanesulfonic acid; N'-{5-[acetyl(hydroxy)amino]pentyl}-N-[5-({4-[(5-aminopentyl)(hydroxy)amino]-4-oxobutanoyl}amino)pentyl]-N-hydroxysuccinamide methanesulfonate (salt); N-[5-[[4-[5-[acetyl(hydroxy)amino]pentylamino]-1,4-dioxobutyl]-hydroxyamino]pentyl]-N'-(5-aminopentyl)-N'-hydroxybutanediamide; methanesulfonic acid; N1-(5-aminopentyl)-N1-hydroxy-N4-(5-(N-hydroxy-4-(5-(N-hydroxyacetamido)pentylamino)-4-oxobutanamido)pentyl)succinamide methanesulfonate; N4-[5-[[4-[[5-(Acetylhydroxyamino)pentyl]amino-1,4-dioxobutyl]hydroxyamino]pentyl]-N1-(5-aminopentyl)-N1-hydroxybutanediamide methanesulfonate; N4-[5-[[4-5-(Acetylhydroxyamino)pentyl]-1,4-dioxobutyl]hydroxyaminopentyl-N1-(5-aminopentyl)-N1-hydroxybutanediamide methanesulfonate